Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Fax Transmission Record - GLASSIA, April 20, 2010

Division of Blood Applications
1401 Rockville Pike, Suite 400N, HFM-380
Rockville, Maryland 20852-1448

FAX  (301) 827-2857
TEL  (301) 827-9170

FAX No. 703-548-7457

To:  -----------------------------(b)(4)---------------------------------------
From: Cherie Ward-Peralta, OBRR/CBER/FDA
Date:   April 20, 2010

This Fax is regarding your submission, STN 125325/0 that was submitted to the Agency on May 29, 2009 as a biologics license application for Alpha-1 Proteinase Inhibitor (Human).  In order to facilitate the review of the BLA, FDA requests the following additional information:


  1. To aid in the ongoing review of your BLA submission, CBER requests an update on your activities toward refining the immunogenicity assay for Kamada-API.  Please include assay development milestones and a working timeline.  CBER would like to stress that a sensitive immunogenicity assay remains a high priority for this program.
  2. ---------------------------------------------------(b)(4)---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  3. In your current manufacturing process, bulk drug substance can be stored ---------(b)(4)----------   ---- prior to being processed to drug product. Please confirm that you will validate the hold time for drug substance in your comparability protocol that evaluates drug substance manufactured from ------------------(b)(4)----------------------.
  4. Please confirm that you will establish upper and lower limits for mixing speed, mixing time, and  -(b)(4)- contact time during the ---------------(b)(4)-------------------- containing -(b)(4)--.

We would appreciate a response to this information request by May 4, 2010. 

Please contact me if you have any questions.


Cherie Ward-Peralta
Regulatory Project Manager
Tel: (301) 827-9170

Page Last Updated: 05/24/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English